Showing 1 - 2 results of 2 for search 'Sanjeev Deva', query time: 0.01s Refine Results
  1. 1
    Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

    Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors by Nicholas Waldron, P Rod Dunbar, Sanjeev Deva, Oh Kyu Yoon, John Ling, Kai-Wen Lin, Dung Thai, Latesh Lad, Ahmed A Othman, Jared M Odegard, Adele Y Wang, Jonathan Nazareno, Edmond Ang

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

    Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors by Yun Zhang, Bhumsuk Keam, Jayesh Desai, Ben Markman, Shahneen Sandhu, Michael Millward, Yoon-Koo Kang, Chia-Chi Lin, Yee Chao, Sanjeev Deva, Jong Seok Lee, Chia-Jui Yen, Michael Jameson, Ming-Mo Hou, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Andrew Hill, Paula Barlow, Chi-Yuan Wu, Liang Liang, John Wu, Virginia Paton

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: